Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD

Sponsor
China National Biotec Group Company Limited (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05075057
Collaborator
Hubei Provincial Center for Disease Control and Prevention (Other), Wuhan Institute of Biological Products Co., Ltd (Industry)
400
Enrollment
1
Arm
8.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .

Condition or DiseaseIntervention/TreatmentPhase
  • Biological: Inactivated COVID-19 vaccine
Phase 4

Detailed Description

The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease were recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively.

Blood samples were collected before the first dose, 28 days after the second dose, before the third dose, 28 days after the third dose and 6 months after the third dose, respectively.

Any local or systemic adverse events that occurred within 21/28 days after vaccination will be recorded.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
subjects aged ≥60 with chronic bronchitis and COPD receive three doses of inactivated COVID-19 vaccinesubjects aged ≥60 with chronic bronchitis and COPD receive three doses of inactivated COVID-19 vaccine
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease
Anticipated Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Experimental Group

A total 400 subjects aged ≥60 years with chronic bronchitis and COPD receive three doses inactivated COVID-19 vaccine on Day 0, Day 21, Day 111, respectively.

Biological: Inactivated COVID-19 vaccine
three doses of inactivated COVID-19 vaccine

Outcome Measures

Primary Outcome Measures

  1. Seroconversion rate [28 days after the 2th dose(Day 49)]

    The rate of seroconversion against coronavirus

  2. Baseline neutralizing antibody level [Before vaccination (Day 0)]

    Neutralizing antibody geometric mean titer(GMT) against coronavirus before vaccination

  3. Neutralizing antibody level [28 days after the 2th dose (Day 49)]

    Neutralizing antibody GMT against coronavirus after the 2th dose

  4. Seroconversion rate [28 days after the 3th dose (Day 139)]

    The rate of seroconversion against coronavirus after the third dose of booster immunization

  5. Neutralizing antibody level [Before the 3th vaccination(Day 111)]

    Neutralizing antibody GMT against coronavirus before the 3th dose

  6. Neutralizing antibody level [28 days after the 3th dose(Day 139)]

    Neutralizing antibody GMT against coronavirus after the 3th dose

  7. Neutralizing antibody level [6 months after the 3th dose (Day 291)]

    Neutralizing antibody GMT against coronavirus after the 3th dose

Secondary Outcome Measures

  1. Adverse events rate [0-21/28 days following vaccinations]

    Analyse the incidence of adverse events following vaccination, both solicited and unsolicited

  2. Serious adverse event rate [0-6 months]

    Report and analyse serious adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
  • Subjects aged 60 and above with full capacity for civil conduct;

  • Chronic bronchitis (or chronic obstructive pulmonary disease) diagnosed by a medical institution at level I or above;

  • Body temperature < 37.3 ° C confirmed by clinical examination before enrollment ;

  • Able and willing to complete the entire study plan during the study follow-up period;

  • Have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol

Exclusion criteria for the first dose::
  • Subjects were previously confirmed cases of COVID-19 or asymptomatic infected persons;

  • Subjects have history of vaccination against COVID-19;

  • Being allergic to any component of vaccines (including excipients) ;

  • Injection of non-specific immunoglobulin within 1 month before enrollment;

  • Injection of live attenuated vaccines within 1 month and injection of other vaccines within 14 days before enrollment;

  • Subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.);

  • Having uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome;

  • Having severe liver and kidney diseases, malignant tumors, acute diseases or acute episodes of chronic diseases;

  • Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukaemia or other autoimmune diseases;

  • Have been diagnosed with thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection;

  • During an acute episode of chronic bronchitis/chronic obstructive pulmonary disease;

  • Other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.

Exclusion criteria for the second dose:
  • Subjects who had vaccine-related adverse reactions after the first dose;

  • Having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction;

  • Having any adverse nervous system reaction after the first dose;

  • During the acute onset of a chronic disease, or the recovery of acute complications less than two weeks;

  • Other reasons for exclusion considered by the investigator.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • China National Biotec Group Company Limited
  • Hubei Provincial Center for Disease Control and Prevention
  • Wuhan Institute of Biological Products Co., Ltd

Investigators

  • Principal Investigator: Xianfeng Zhang, Hubei Provincial Center for Disease Control and Prevention

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
China National Biotec Group Company Limited
ClinicalTrials.gov Identifier:
NCT05075057
Other Study ID Numbers:
  • WIBP2021COPD
First Posted:
Oct 12, 2021
Last Update Posted:
Oct 12, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2021